Hexarelin is a synthetic peptide that stimulates the body’s release of growth hormone. It belongs to a class of compounds called growth hormone releasing peptides (GHRPs) and is one of the most potent in that family. Built from a chain of six amino acids, hexarelin is closely related to an older peptide called GHRP-6 but was engineered to be more stable and more powerful.
How Hexarelin Works
Hexarelin triggers growth hormone release by binding to a receptor called GHS-R1a, located in the pituitary gland and hypothalamus. This is the same receptor that ghrelin, the body’s natural “hunger hormone,” uses to signal for growth hormone. When hexarelin locks onto this receptor, the pituitary responds by releasing a pulse of growth hormone into the bloodstream.
What makes hexarelin unusual is that it doesn’t stop there. It also binds to a second receptor called CD36, which is found on heart muscle cells and the small blood vessels that supply the heart. This dual-receptor activity sets hexarelin apart from most other growth hormone releasing peptides. The binding strength of hexarelin at the ghrelin receptor is comparable to ghrelin itself (half-maximal effective concentrations of 1.7 and 1.0 nanomoles per liter, respectively), but its additional interaction with CD36 gives it effects that go beyond simple growth hormone release.
Growth Hormone Release Compared to Other Peptides
Hexarelin produces a noticeably stronger growth hormone response than its predecessor GHRP-6 and even outperforms the body’s own growth hormone releasing hormone (GHRH). In a study of healthy young volunteers, a single intravenous dose of hexarelin at 1 microgram per kilogram of body weight produced roughly twice the growth hormone output of an equivalent dose of GHRH. Increasing the dose to 2 micrograms per kilogram pushed the response even higher, and the results were highly reproducible across repeated tests.
Hexarelin also works through multiple routes of administration. Subcutaneous injection retained about 77% of the biological availability seen with intravenous delivery. Intranasal administration dropped to around 5%, and oral delivery was far less efficient at roughly 0.3%. This is why injection has remained the primary route studied in research settings.
Cardiovascular Effects Through CD36
The heart-related effects of hexarelin have drawn significant research interest. When hexarelin activates CD36 receptors on heart cells, it increases coronary perfusion pressure in a dose-dependent way, meaning blood flow through the heart’s own vessels responds proportionally to the amount of hexarelin present. This effect disappears entirely in hearts that lack the CD36 receptor, confirming that this specific receptor is responsible.
Researchers identified the CD36 protein on both heart muscle cells and the tiny endothelial cells lining cardiac blood vessels. In animal models, hexarelin has shown cardioprotective properties, and its higher potency compared to ghrelin is thought to come largely from this CD36 interaction rather than its activity at the ghrelin receptor alone. Studies in insulin-resistant mice also found that hexarelin improved abnormal lipid metabolism, suggesting effects on fat processing that extend beyond the heart.
Tolerance Develops Quickly
One of hexarelin’s most significant limitations is how rapidly the body adjusts to it. In laboratory studies, measurable desensitization of the ghrelin receptor’s signaling occurred within 2 to 5 minutes after the first dose. This means the receptor essentially dials down its response almost immediately, reducing the growth hormone pulse with repeated or continuous exposure.
This fast-onset tolerance is a key practical consideration. The growth hormone increase hexarelin produces is transient by nature, and sustained use tends to yield diminishing returns. This desensitization happens at the level of the receptor’s internal signaling cascade, not just at the surface, which makes it difficult to overcome simply by increasing the dose.
Effects on Other Hormones
Hexarelin’s activity isn’t limited to growth hormone. It also causes mild increases in prolactin, ACTH (a hormone that signals the adrenal glands), and cortisol. In human studies comparing hexarelin to other hormonal triggers, the prolactin increase was consistently smaller than what standard prolactin-stimulating agents produce. The cortisol and ACTH increases, however, were comparable to those caused by the body’s own cortisol-releasing hormone.
These secondary hormonal effects are shared across the GHRP family. Both hexarelin and a related peptide called GHRP-2 raised prolactin, ACTH, and cortisol to similar degrees at all tested doses. The responses were dose-dependent and also varied with age, with younger adults generally showing stronger growth hormone output. While the prolactin and cortisol elevations are described as “slight,” they represent a lack of full specificity: hexarelin doesn’t exclusively target growth hormone secretion.
Pharmacokinetics
In animal studies, hexarelin had a half-life of approximately 76 minutes after intravenous injection. This relatively short window means the peptide is cleared from the body within a few hours, and the growth hormone pulse it triggers is similarly brief. The volume of distribution was large relative to body size, indicating that hexarelin spreads widely through tissues rather than staying confined to the bloodstream.
Regulatory Status
Hexarelin has never received FDA approval for any medical use. It remains an investigational compound studied primarily in research contexts. The World Anti-Doping Agency (WADA) lists growth hormone secretagogues, including hexarelin, as prohibited substances at all times, both in and out of competition. Athletes tested for doping can face sanctions for hexarelin use regardless of when it was administered relative to an event.
In the United States, the FDA has evaluated related growth hormone secretagogue compounds and has generally not supported adding them to approved compounding lists. Hexarelin is available through research chemical suppliers, but it is not legally marketed as a drug or dietary supplement for human use.